General
Preferred name
tinengotinib
Synonyms
TT 00420 ()
TT-00420 ()
P&D ID
PD164428
CAS
2230490-29-4
Tags
available
drug candidate
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The chemical structure for tinengotinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a tyrosine kinase inhibitor and antineoplastic agent. The SMILES provided a match to TransThera Sciences' clinical lead TT-00420 via PubChem. TT-00420 appears to be an orally administered multi‐kinase inhibitor that targets cell proliferation, angiogenesis, and immune-oncology, through inhibition of Aurora kinases A/B and Janus kinases (involved in cytokine signalling) and receptor tyrosine kinases such as FGFRs and VEGFRs (which play roles in proliferation and angiogenesis) . (GtoPdb)
Compound Sets
6
ChEMBL Drugs
CHEMBL5314430
DrugBank
DB17384
Guide to Pharmacology
11887
MedChem Express Bioactive Compound Library
HY-145601
PKIDB
Selleckchem Bioactive Compound Library
tinengotinib
External IDs
10
Properties
(calculated by RDKit )
Molecular Weight
394.13
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
5
Aromatic Ring Count
3
cLogP
3.83
TPSA
78.43
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
7.0
QED
0.54
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Cell Cycle/DNA Damage
Epigenetics
Protein Tyrosine Kinase/RTK
Target
Aurora Kinase
VEGFR
Source data